North America Women’s Health Diagnostics Market - Market Share Analysis, Industry Trends & Statistics, and Growth Forecasts 2020 - 2035

Posted On 31-07-2025

• Expanded Awareness and Screening Initiatives: The increased focus on preventive healthcare and early disease detection has led to a surge in women undergoing regular diagnostic tests for breast cancer, cervical cancer, and reproductive health. Organizations such as Hologic Inc. and Quest Diagnostics have launched comprehensive awareness campaigns and partnered with healthcare institutions to improve accessibility and adoption of diagnostic services. These initiatives are especially impactful in rural and underserved areas, driving significant growth in test volumes and market revenues.
• Technological Advancements in Diagnostic Equipment: Industry players like Roche Diagnostics and Siemens Healthineers are leading the innovation in diagnostic technologies, introducing automated, high-sensitivity platforms for genetic and molecular testing. The integration of AI-powered analytics in imaging and laboratory diagnostics is enabling more precise detection and earlier diagnosis of women-specific conditions, such as ovarian cancer and endometriosis. Such advancements are further fueling the adoption of advanced diagnostic tools across North America.

• Growing Adoption of Point-of-Care (POC) Testing: Major companies like Abbott Laboratories have accelerated the development and distribution of point-of-care diagnostic solutions, enabling rapid, on-site testing for various women’s health conditions. The pandemic period increased demand for remote and at-home diagnostic tools, which is now being extended to women’s health diagnostics. The convenience and timely results offered by POC testing are transforming patient care pathways and streamlining diagnostic workflows in clinics and outpatient centers.
• Integration of Digital Health Platforms: There is a notable trend towards integrating diagnostics results with digital health platforms and patient portals. Companies such as BD (Becton, Dickinson and Company) and GE Healthcare are providing interoperable software solutions that allow women and clinicians to track and manage health outcomes via mobile apps and cloud-based systems. This integration supports personalized medicine, improves follow-up care, and increases patient engagement in their health management.

• Expansion of Genetic and Genomic Testing: Companies like Myriad Genetics are capitalizing on the increasing demand for genetic and genomic testing for hereditary cancers and reproductive health conditions. As awareness grows, genetic counseling and testing for BRCA mutations and other inherited disorders is creating a substantial opportunity for new diagnostic services and revenue streams.
• Untapped Emerging Markets Within North America: Despite high market penetration in the US, opportunities exist for companies to expand services in Canada and Mexico through collaboration with public health authorities and localized R&D initiatives, unlocking new customer segments and driving market growth.

• In February 2024, Hologic Inc. introduced its new Genius Digital Diagnostics System across select U.S. hospitals, leveraging artificial intelligence to improve cervical cancer screening accuracy. The launch was accompanied by training programs for clinicians, and early pilot results indicated a 15% faster diagnosis timeline relative to traditional cytology.
• In March 2024, Roche Diagnostics received FDA clearance for its cobas HPV test, designed for self-sampling by women at home, making it the first at-home HPV testing kit available in the U.S. Roche is collaborating with telehealth platforms to provide remote consultations based on test results, expanding the company’s digital health ecosystem.
• In May 2024, Myriad Genetics signed a multi-year partnership with major Canadian healthcare providers to expand access to hereditary cancer testing and genetic counseling. The agreement aims to integrate Myriad’s molecular diagnostics platforms across academic and community health centers in Canada, increasing testing volumes and improving early cancer detection.